Intravenous administration of nifekalant hydrochloride for the prevention of ischemia-induced ventricular tachyarrhythmia in patients with renal failure undergoing hemodialysis

Masafumi Myoishi, Satoshi Yasuda, Shunichi Miyazaki, Kazuyuki Ueno, Isao Morii, Kazuhiro Satomi, Yoritaka Otsuka, Atsushi Kawamura, Takashi Kurita, Shiro Kamakura, Hiroshi Nonogi

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)

Abstract

Excretion in the urine is an important pathway for the elimination of nifekalant hydrochloride (NIF), a novel class III antiarrhythmic agent. Three patients with renal failure were undergoing hemodialysis and receiving NIF for the prevention of ischemia-induced ventricular tachyarrhythmia. Because NIF is not dialyzed, dose adjustment at relatively low concentrations was required, with monitoring of the QT interval.

Original languageEnglish
Pages (from-to)898-900
Number of pages3
JournalCirculation Journal
Volume67
Issue number10
DOIs
Publication statusPublished - 2003 Oct 1
Externally publishedYes

Keywords

  • Antiarrhythmic agents
  • Hemodialysis
  • Ventricular tachyarrhythmia

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Intravenous administration of nifekalant hydrochloride for the prevention of ischemia-induced ventricular tachyarrhythmia in patients with renal failure undergoing hemodialysis'. Together they form a unique fingerprint.

Cite this